Suppr超能文献

三种用作角膜内皮细胞体外扩增补充剂的人血小板裂解物的比较。

Comparison of three human platelet lysates used as supplements for in vitro expansion of corneal endothelium cells.

作者信息

Wang Tsung-Jen, Chen Ming-Sheng, Chou Ming-Li, Lin Hsiu-Chen, Seghatchian Jerard, Burnouf Thierry

机构信息

Department of Ophthalmology, Taipei Medical University Hospital, Taipei, Taiwan; Department of Ophthalmology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.

Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.

出版信息

Transfus Apher Sci. 2017 Oct;56(5):769-773. doi: 10.1016/j.transci.2017.08.021. Epub 2017 Aug 31.

Abstract

BACKGROUND

Human platelet lysates (HPLs) are emerging as the new gold standard supplement of growth media for ex vivo expansion of cells for transplant. However, variations do exist in the way how HPLs are prepared. In particular, uncertainties still exist regarding the type of HPL most suitable for corneal endothelium cells (CEC) expansion, especially as these cells have limited proliferative capacity.

MATERIAL AND METHODS

Three distinct HPL preparations were produced, with or without calcium chloride/glass beads activation, and with or without heat treatment at 56°C for 30min. These HPLs were used to supplement basal D-MEM growth medium, each at a protein concentration equivalent to that of 10% fetal bovine serum (FBS; control). Impact on CEC (BCE C/D-1b cells) in vitro morphology, viability and capacity to express Zonula occludens-1 (ZO-1) tight junction marker was assessed by Western blotting.

RESULTS

BCE C/D-1b cells grown in all HPL supplements exhibited four of essential characteristic properties: adhesion capacity, microscopic morphology and viability similar to that observed when using 10% FBS. In addition, Western blots analysis revealed an expression of the ZO-1 marker by BCE C/D-1b cells in all conditions of culture.

CONCLUSION

CECs can expand ex vivo in a basal medium supplemented with the three HPLs without noticeable difference compared to FBS supplement. These data support further studies to evaluate the potential to use HPLs as a clinical-grade xeno-free supplement of CEC for corneal transplant.

摘要

背景

人血小板裂解物(HPLs)正成为用于细胞体外扩增以进行移植的生长培养基的新金标准补充剂。然而,HPLs的制备方式确实存在差异。特别是,关于最适合角膜内皮细胞(CEC)扩增的HPL类型仍存在不确定性,尤其是因为这些细胞的增殖能力有限。

材料与方法

制备了三种不同的HPL制剂,有或没有氯化钙/玻璃珠激活,以及有或没有在56°C热处理30分钟。这些HPLs用于补充基础D-MEM生长培养基,每种的蛋白质浓度相当于10%胎牛血清(FBS;对照)。通过蛋白质印迹法评估对CEC(BCE C/D-1b细胞)体外形态、活力和表达紧密连接蛋白-1(ZO-1)紧密连接标志物能力的影响。

结果

在所有HPL补充剂中生长的BCE C/D-1b细胞表现出四个基本特征:黏附能力、微观形态和活力与使用10%FBS时观察到的相似。此外,蛋白质印迹分析显示在所有培养条件下BCE C/D-1b细胞均表达ZO-1标志物。

结论

与FBS补充剂相比,CECs可以在补充有三种HPLs的基础培养基中进行体外扩增,且无明显差异。这些数据支持进一步研究以评估使用HPLs作为角膜移植中CEC的临床级无动物源补充剂的潜力。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验